Dr Kilian Kelly has over 20 years’ experience in biopharmaceutical research and development, including more than 13 years focussed on development of mesenchymal stem (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then acted as Chief Operating Officer from May 2019, before taking on the role of CEO & MD in July 2023. At Cynata, he has overseen all stages of the development of the Cymerus™ iPSC-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.

Dr Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca. He holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen and a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow. He is a graduate and member of the Australian Institute of Company Directors (AICD), and a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR) and the Royal Pharmaceutical Society. He also currently serves on the ISSCR Best Practices Regulatory Working Group and the Industry Interface Committee of the Center for Commercialisation of Regenerative Medicine (CCRM) Australia.

Dr Mathias Kroll has over 25 years’ experience in biopharmaceutical research and business development. He joined the Company in April 2024 as Chief Business Officer. Dr. Kroll has extensive global experience in biopharmaceutical business transactions of all kinds and has created and managed a large number of partnerships ranging in value up to several billion dollars.

His previous appointments are Chief Commercial Officer, QIMR Berghofer (AUS), Chief Executive Officer, InProTher ApS (DK, now Hervolution Therapeutics), Global Head of Business Development, Bavarian Nordic (DK), Sr Director Global Business Development, GlaxoSmithKline Vaccines (BE), Assoc. Product Director and Global Brand Manager, UCB (BE), Assoc. Director Business Development, UCB Japan (JP), Research Unit Head, Sanofi (FR), Laboratory Head, Bayer Healthcare (DE), Vis. Assoc. Consultant, Boston Consulting Group (DE), and Research Associate, INSERM (FR). Following studies and research work performed at the Universities of Dusseldorf (DE), Paris (FR), North Carolina at Chapel Hill (USA), and at IMD in Lausanne (CH), Dr Kroll holds Master’s degrees in Chemistry, Biology, and Business Administration, a diploma in Molecular Virology, and a PhD in Viral Immunology for work performed at Pasteur Institute (FR). He is a member of the Australian Institute of Company Directors. He also serves on the Selection Panel of CUREator, Australia’s national biotech incubator.

Dr Airey is an accomplished biopharmaceutical executive and physician with broad international experience in the successful development and commercialisation of pharmaceutical products including novel biological agents. She has been involved in the design and execution of multiple clinical trials from early through to late stage, encompassing a wide range of therapeutic categories in multiple geographies. Dr Airey joined Cynata in October 2021 from CSL Limited, where she was Director, Translational Development. Prior to CSL, Dr Airey was a Clinical Development Physician at Seqirus, a CSL company, and earlier held a range of medical positions within biotech, pharmaceutical and clinical research companies. Her career path has led to her playing important roles in the market approvals of several drug products.